<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>To evaluate the effect of recombinant human erythropoietin (rHuEpo) on the <z:chebi fb="34" ids="35143">haemoglobin</z:chebi> level and transfusion requirement in low-risk <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>), 87 patients were enrolled in a randomized double-blind placebo-controlled study, 44 patients were assigned to epoetin alpha (150 U/kg/d s.c. for 8 weeks) and 43 to placebo arms </plain></SENT>
<SENT sid="1" pm="."><plain><z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> types were homogenous in both groups: refractory <z:hpo ids='HP_0001903'>anaemia</z:hpo> (RA) 47.7-48.8%. refractory <z:hpo ids='HP_0001903'>anaemia</z:hpo> with ringed sideroblasts (<z:mp ids='MP_0011356'>RAS</z:mp>) 20.5-25.6%, refractory <z:hpo ids='HP_0001903'>anaemia</z:hpo> with excess of blasts (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e>) (blasts &lt; 10%) 31.8-25.6%, 14/38 evaluable patients responded to epoetin alpha versus 4/37 to placebo (P=0.007) </plain></SENT>
<SENT sid="2" pm="."><plain>50% of RA responded to epoetin alpha versus 5.9% to placebo (P=0.0072), <z:mp ids='MP_0011356'>RAS</z:mp> 37.5% v 18.2% (P=0.6) and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e> 16.7% v 11.1% (P=1.00) </plain></SENT>
<SENT sid="3" pm="."><plain>60% of non-pretransfused patients responded to epoetin alpha (Hb 8.35&lt; or = 0.73 to 10.07+/-1.87 g/dl), whereas a slight decrease was observed in the placebo group (8.4+/-0.66 to 8.19+/-0.92 g/dl) (P=0.0004) </plain></SENT>
<SENT sid="4" pm="."><plain>Percentage of transfused patients was similar in both arms </plain></SENT>
<SENT sid="5" pm="."><plain>Basal erythropoietin (Epo) serum levels &gt; 200 mU/l predicted for a non-response </plain></SENT>
<SENT sid="6" pm="."><plain>At week 4 sTfR levels were increased &gt; 50% in responders (P=0.013), whereas an increase &lt; 18% predicted for non-response (P=0.006) </plain></SENT>
<SENT sid="7" pm="."><plain>Leucocyte and platelet counts were not influenced by epoetin alpha treatment </plain></SENT>
<SENT sid="8" pm="."><plain>Adverse events occurred in 31.8% of the rHuEpo-treated versus 42.99%) of the placebo-treated patients (P=0.2), and seven patients did not complete the course </plain></SENT>
<SENT sid="9" pm="."><plain>In conclusion, rHuEpo was effective in the treatment of low-risk <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
<SENT sid="10" pm="."><plain>RA subtype, no transfusions prior to rHuEpo therapy, and low basal Epo levels were associated with higher probability of response </plain></SENT>
<SENT sid="11" pm="."><plain>Soluble transferrin receptor level at the fourth week was an early predictor of response </plain></SENT>
</text></document>